|
|
Drugs for Recurrent Respiratory Papillomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show all 34)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Cidofovir | approved | Phase 4, Phase 2 | 33 | 113852-37-2 | 60613 | (2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine (S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine (S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid (S)-HPMPC (s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid ({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine 113852-37-2 120362-37-0 (hydrochloride salt) 149394-66-1 AC-1666 AC1L1TLB AC1Q6C68 AKOS005145721 C8H14N3O6P CDV CHEBI:3696 | CHEMBL152 CID60613 Cidofovir Cidofovir (Vistide) Cidofovir (anhydrous) Cidofovir Anhydrous Cidofovir anhydrous Cidofovirum DB00369 Forvade GS 0504 GS 504 GS-0504 GS-504 GS504 HPMPC HSDB 7115 LS-106432 MolPort-005-935-597 NSC742135 S1516_Selleck UNII-768M1V522C Vistide Vistide, Cidofovir [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid [(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid |
| | 2 | | Anti-Infective Agents | | Phase 4, Phase 2 | 21402 | | | | 3 | | Antiviral Agents | | Phase 4, Phase 3, Phase 2 | 9732 | | | | 4 | | Immunoglobulins | | Phase 3, Phase 2 | 6045 | | | | 5 | | Antibodies | | Phase 3, Phase 2 | 6045 | | | | 6 | | Vaccines | | Phase 3, Early Phase 1 | 6428 | | | | 7 | | Bevacizumab | approved, investigational | Phase 2, Phase 1 | 1968 | 216974-75-3 | | 216974-75-3 Avastin Avastin (TN) Bevacizumab Bevacizumab (genetical recombination) | Bevacizumab (genetical recombination) (JAN) D06409 R-435 anti-VEGF monoclonal antibody antiVEGF bevacizumab | |
| | 8 | | Celecoxib | approved, investigational | Phase 2 | 435 | 169590-42-5 | 2662 | 169590-42-5 184007-95-2 1oq5 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide AC-4228 AC1L1E6K AI-525 BIDD:GT0408 BRD-K02637541-001-02-4 BSPBio_003596 Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl) C07589 C105934 C17H14F3N3O2S CCRIS 8679 CEL CEP-33222 CHEBI:41423 CHEMBL118 CID2662 CPD000550473 Celebra Celebrex Celebrex (TN) Celebrex, Celebra, Celecoxib Celecox Celecoxi Celecoxib Celecoxib (JAN/USAN/INN) Celecoxib (SC-58635) Celecoxib [Old RN] Celecoxib [USAN] Celecoxibum Celocoxib Célécoxib D00567 DB00482 DivK1c_000893 Eurocox FT-0080064 HMS1922G14 HMS2089L18 HMS2093I07 HMS502M15 HSDB 7038 I01-1033 IDI1_000893 KBio1_000893 KBio2_000912 | KBio2_002351 KBio2_003480 KBio2_004919 KBio2_006048 KBio2_007487 KBio3_002830 KBio3_003037 KBioGR_000723 KBioGR_002351 KBioSS_000912 KBioSS_002354 LS-31667 MLS001165684 MLS001195656 MLS001304708 Medicoxib MolPort-002-885-815 NCGC00091455-01 NCGC00091455-02 NCGC00091455-03 NCGC00091455-04 NCI60_041049 NINDS_000893 NSC719627 Onsenal P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide Pfizer brand of celecoxib S1261_Selleck SAM002589995 SC 58635 SC-58553, SC-58635 SC-58635 SC58635 SMR000550473 SPBio_001512 SPECTRUM1503678 Solexa Spectrum2_001576 Spectrum3_001996 Spectrum4_000182 Spectrum5_001324 Spectrum_000432 TL8001323 TPI-336 UNM-0000305813 Xilebao YM 177 YM-177 YM177 ZINC02570895 cMAP_000027 celecoxib p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide | |
| | 9 | | Pembrolizumab | approved | Phase 2 | 421 | 1374853-91-4 | | | | 10 | | Vitamin A | approved, nutraceutical, vet_approved | Phase 2 | 468 | 11103-57-4, 68-26-8 | 445354 | (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol .alpha.lin .alpha.sterol .beta.-Retinol 11103-57-4 13123-33-6 1341-18-0 1406-67-3 17104-91-5 1rbp 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer 4-06-00-04133 (Beilstein Handbook Reference) 53637-36-8 5979-23-7 68-26-8 95144_FLUKA 95144_SIGMA 95146_FLUKA 95146_SIGMA A-Mulsal A-Sol A-Vi-Pel A-Vitan AC-11701 AC1L9HU3 AC1Q7BU9 ACON ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1) AR-1L3057 ATAV Afaxin Agiolan Agoncal Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol Alcovit A All Trans Retinol All-trans retinol All-trans-Retinol Alphalin Alphasterol Anatola Anatola A Anti-infective vitamin Antixerophthalmic vitamin Antixerophthalmisches Vitamin Aoral Apexol Apostavit Aquasol A Parenteral Aquasynth Atars Avibon Avita Avitol Axerol Axerophthol Axerophtholum BIDD:PXR0102 BRN 0403040 Bentavit A Biosterol C00473 C17276 C20H30O CCRIS 5444 CHEBI:17336 CHEMBL986 CID445354 Chocola A Cylasphere D014801 D06543 DB00162 Del-VI-A Disatabs Tabs Dofsol Dohyfral A EINECS 200-683-7 EINECS 234-328-2 Epiteliol HMS1921B04 HMS2092L13 HMS501I08 HSDB 815 Hi-A-Vita Homagenets Aoral Homagenets aorl Hydrovit A IDI1_000486 LMPR01090001 LPK LS-1578 Lard Factor M.V.C. 9+3 M.V.I.-12 | MLS001066379 MLS001074751 MolPort-001-785-962 Mvc Plus Myvpack NCGC00091784-01 NCGC00091784-02 NCGC00091784-03 NCGC00091784-04 NCGC00091784-05 NCGC00091784-06 NSC 122759 NSC122759 Nio-A-Let Oleovitamin A Ophthalamin Plivit A Prepalin R7632_SIGMA Retin-11,12-t2-ol (9CI) Retinol Retinol [INN:BAN] Retinol solution Retinol, all-trans- (8CI) Retinol-(cellular-retinol-binding-protein) Retinolo Retinolo [DCIT] Retinolum Retinolum [INN-Latin] Retrovitamin A Ro-a-vit Rovimix A 500 SDCCGMLS-0066724.P001 SMP2_000102 SMR000112036 SPECTRUM1501203 ST057232 Sehkraft A Solu-A Spectrum5_000993 Spectrum5_001997 Super A Testavol Testavol S Thalasphere UNII-81G40H8B0T UNII-G2SH0XKK91 Vaflol Vafol Veroftal Vi-.alpha. Vi-Alpha Vi-Dom-A Vi-a Vio-A Vitamin A Vitamin A (Feed) Vitamin A (USP) Vitamin A alcohol Vitamin A alcohol (VAN) Vitamin A cryst Vitamin A1 Vitamin A1 alcohol Vitamin A1 alcohol, all trans Vitamin- A Vitamin- A alcohol Vitamin- A alcohol solution Vitamin- A1 Vitamin-?A Vitamin-?A alcohol Vitamin-?A alcohol solution Vitamin-?A1 Vitamine A Vitaminum A Vitavel A Vitavel-A Vitpex Vogan Vogan-Neu Vogan-nu WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1 Wachstumsvitamin ZINC03831417 Zinosan N [11,12-3H]-Retinol alin all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol all-trans-Retinol all-trans-Retinyl alcohol all-trans-Vitamin A all-trans-Vitamin A alcohol all-trans-Vitamin A1 all-trans-retinol all-trans-retinyl alcohol all-trans-vitamin A alcohol b-Retinol beta-Retinol retinol tROL trans-Retinol trans-Retinol acid (Vitamin A) trans-Vitamin A alcohol trans-retinol |
| | 11 | | Peripheral Nervous System Agents | | Phase 2 | 22776 | | | | 12 | | Angiogenesis Inhibitors | | Phase 2, Phase 1 | 4143 | | | | 13 | | Cyclooxygenase Inhibitors | | Phase 2 | 2778 | | | | 14 | | Angiogenesis Modulating Agents | | Phase 2, Phase 1 | 4072 | | | | 15 | | Analgesics, Non-Narcotic | | Phase 2 | 6260 | | | | 16 | | Cyclooxygenase 2 Inhibitors | | Phase 2 | 616 | | | | 17 | | Anti-Inflammatory Agents | | Phase 2 | 10355 | | | | 18 | | Analgesics | | Phase 2 | 11287 | | | | 19 | | Anti-Inflammatory Agents, Non-Steroidal | | Phase 2 | 4295 | | | | 20 | | Antirheumatic Agents | | Phase 2 | 10627 | | | | 21 | | Pharmaceutical Solutions | | Phase 2 | 7793 | | | | 22 | | Antibodies, Monoclonal | | Phase 2 | 3795 | | | | 23 | | Retinol palmitate | | Phase 2 | 468 | | | | 24 | | retinol | Nutraceutical | Phase 2 | 468 | | | | 25 | | Ergocalciferol | approved, nutraceutical | Phase 1 | 1232 | 50-14-6 | 5280793 | 'Ergosterol irradiated' (+)-Vitamin D2 (3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol (3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol (3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol (3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol (3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol (5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol (5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol (5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol 22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol 31316-19-5 4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol 47768_SUPELCO 50-14-6 7489-18-1 7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87 8017-28-5 9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol 9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol 9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol 9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol 95220_FLUKA 95220_SIGMA AC-1355 AC1L1FIE AC1NQXLH AC1NS4DE AC1NS9GI AC1NSSVD AC1NWAM3 AC1O5EDK AC1O6WAM ACon1_002187 Activated ergosterol BPBio1_000418 BSPBio_000380 BSPBio_001974 Buco-D C05441 C28H44O CALCIFEROL IN A GELATIN MATRIX CALCIFEROL, U.S.P. CHEBI:28934 CHEMBL1536 CID11003810 CID3249 CID5280793 CID5315257 CID5353610 CID5356615 CID5702050 CID6432478 CID6536972 Calciferol Calciferol (TN) Calciferol (vitamin D2) Calciferolum Calciferon 2 Condacaps Condocaps Condol Crtron Crystallina D-Arthin D-Tracetten D00187 DB00153 Daral Davitamon D Davitin De-rat concentrate Decaps Dee-Osterol Dee-Ron Dee-Ronal Dee-Roual Deltalin Deratol Detalup Diactol Divit urto Doral Drisdol Drisdol (TN) E5750_SIGMA EINECS 200-014-9 Ercalciol Ergocalciferol Ergocalciferol (D2) Ergocalciferol (JP15/USP) Ergocalciferol [INN:BAN:JAN] Ergocalciferol oil Ergocalciferol: Vitamin D | Ergocalciferolo Ergocalciferolo [DCIT] Ergocalciferols Ergocalciferolum Ergocalciferolum [INN-Latin] Ergorone Ergosterol activated Ergosterol irradiated Ergosterol, irradiated Ertron Fortodyl Geltabs Geltabs Vitamin D HMS1920K20 HMS2091B19 HMS502I07 HSDB 819 Haliver Hi-Deratol Hyperkil I05-0022 IDI1_000805 Infron Irradiated ergosta-5,7,22-trien-3-beta-ol Irradiated ergosta-5,7,22-trien-3.beta.-ol Irradiated ergosta-5,7,22-trien-3beta-ol Irradiated ergosterol LMST03010001 LMST03010014 LS-3228 MEGxm0_000466 MLS001332467 MLS001332468 Metadee Mina D2 MolPort-001-740-057 MolPort-001-793-930 MolPort-002-526-645 MolPort-003-666-178 MolPort-006-822-629 Mulsiferol Mykostin NCGC00142497-01 NCGC00179579-01 NCGC00179579-02 NSC 62792 NSC62792 Novovitamin-D Oleovitamin D Oleovitamin D, Synthetic Oleovitamin D2 Osteil Ostelin Prestwick3_000420 Prestwick_554 Radiostol Radstein Radsterin Rodine C Rodinec SMR000857106 SPECTRUM1500276 ST057150 STOCK1N-53397 Shock-ferol Shock-ferol sterogyl Sorex C.R Sorex C.R. Spectrum5_000666 Sterogyl Synthetic Vitamin D UNII-VS041H42XC Uvesterol D Uvesterol-D VITAMIN D2 VITAMIN D2 WATER DISPERSABLE U.S.P. VITAMIN_D2 Vigantol Vio D Vio-D Viostdrol Viosterol Viosterol in Oil Vitamin D2 Vitamin- D2 Vitamin-?D2 Vitamina D2 Vitavel-D WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ ZINC04474571 ZINC04629876 beta-Ol bmse000510 component of Geltabs Vitamin D delta-Arthin delta-Tracetten ergocalciferol vitamin d-2 | |
| | 26 | | Trace Elements | | Phase 1 | 5802 | | | | 27 | | vitamin d | | Phase 1 | 1653 | | | | 28 | | Micronutrients | | Phase 1 | 5802 | | | | 29 | | Bone Density Conservation Agents | | Phase 1 | 3266 | | | | 30 | | Vitamins | | Phase 1 | 5095 | | | | 31 | | Ergocalciferols | | Phase 1 | 1232 | | | | 32 | | Calciferol | Nutraceutical | Phase 1 | 1334 | | | | 33 | | Vitamin D2 | Nutraceutical | Phase 1 | 1232 | | | | 34 | | Pepsin A | | | 14 | | |
Interventional clinical trials: (show all 20)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Use of Cidofovir for Recurrent Respiratory Papillomatosis | Completed | NCT00205374 | Phase 4 | | 2 | Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") | Terminated | NCT00747461 | Phase 4 | | 3 | Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis | Active, not recruiting | NCT01375868 | Phase 3 | | 4 | 4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children | Not yet recruiting | NCT01995721 | Phase 3 | | 5 | Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis | Withdrawn | NCT01058317 | Phase 2, Phase 3 | | 6 | Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis | Completed | NCT00571701 | Phase 2 | | 7 | A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis | Completed | NCT00038714 | Phase 2 | | 8 | Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis | Recruiting | NCT02555800 | Phase 2 | | 9 | Avelumab for People With Recurrent Respiratory Papillomatosis | Recruiting | NCT02859454 | Phase 2 | | 10 | Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement | Recruiting | NCT02632344 | Phase 2 | | 11 | New Therapy of Laryngeal Papilloma In Children | Terminated | NCT00591305 | Phase 2 | | 12 | Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP) | Completed | NCT01020747 | Phase 1 | | 13 | Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP) | Not yet recruiting | NCT02854761 | Phase 1 | | 14 | Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease | Withdrawn | NCT00733252 | Phase 1 | | 15 | Multi-Center, Randomized Trial of the Pulsed Dye Laser for JORRP | Completed | NCT00550914 | | | 16 | Human Papillomatosis Genotyping of Children in Thailand | Completed | NCT01304966 | | | 17 | Human Papillomavirus 6/11 in the Lower Airway of Neonates | Completed | NCT00549250 | | | 18 | Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions | Completed | NCT02217358 | | | 19 | Recurrent Respiratory Papillomatosis and Extraesophageal Reflux | Recruiting | NCT02592902 | | | 20 | Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis | Withdrawn | NCT00829608 | Early Phase 1 |
|
